Cargando…
IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat
INTRODUCTION: A large subset of diffusely infiltrative gliomas contains a gain-of-function mutation in isocitrate dehydrogenase 1 or 2 (IDH1/2(mut)) which produces 2-hydroxglutarate, an inhibitor of α-ketoglutarate-dependent DNA demethylases, thereby inducing widespread DNA and histone methylation....
Autores principales: | Sears, Thomas K., Horbinski, Craig M., Woolard, Kevin D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437887/ https://www.ncbi.nlm.nih.gov/pubmed/34424450 http://dx.doi.org/10.1007/s11060-021-03829-0 |
Ejemplares similares
-
R132H IDH1 sensitizes glioma to the antiproliferative and cytotoxic effects of BET inhibition
por: Sears, Thomas K., et al.
Publicado: (2022) -
Postoperative risk of IDH-mutant glioma–associated seizures and their potential management with IDH-mutant inhibitors
por: Drumm, Michael R., et al.
Publicado: (2023) -
Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid
por: Fujioka, Yutaka, et al.
Publicado: (2021) -
Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
por: Unruh, Dusten, et al.
Publicado: (2019) -
Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas
por: Cho, Nicholas S, et al.
Publicado: (2022)